| Date Filed | Type | Description |
| 09/25/2020 |
4
| Polinsky David (CFO) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Granted 5,000 shares
@ $0 |
|
| 09/01/2020 |
8-K
| Other Events |
| 09/01/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 08/06/2020 |
GN
| Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®? (devimistat) for Patients with Metastatic Pancreatic Cancer |
| 07/21/2020 |
GN
| Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 06/09/2020 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 06/09/2020 |
10-Q
| Quarterly Report for the period ended April 30, 2020 |
| 05/26/2020 |
GN
| Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program |
| 05/07/2020 |
GN
| Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models |
| 05/05/2020 |
GN
| Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer |
| 04/28/2020 |
GN
| MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals' Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt's Lymphoma/Leukemia |
| 04/23/2020 |
GN
| Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 04/22/2020 |
4
| JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Disposed of 32,711 shares
@ $0 |
|
| 04/06/2020 |
4
| JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Disposed of 787,163 shares
@ $0
Disposed of 4,306,738 shares
@ $0 |
|
| 03/26/2020 |
8-K
| Quarterly results |
| 03/05/2020 |
10-Q
| Quarterly Report for the period ended January 31, 2020 |
| 03/05/2020 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 03/03/2020 |
GN
| Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer |
| 02/12/2020 |
SC 13G/A
| DIMENSIONAL FUND ADVISORS LP reports a 5.6% stake in RAFAEL HOLDINGS INC-CLASS B |
| 02/04/2020 |
8-K
| Other Events |
| 01/28/2020 |
4
| ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Paid exercise price by delivering 5,238 shares
@ $22.155, valued at
$116k
|
|
| 01/21/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 01/14/2020 |
GN
| Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer |
| 01/13/2020 |
GN
| Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference |
| 01/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/10/2019 |
8-K
| Quarterly results |
| 12/09/2019 |
10-Q
| Quarterly Report for the period ended October 31, 2019 |
| 12/09/2019 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 12/03/2019 |
GN
| Data on Rafael Pharmaceuticals' CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition |
| 12/03/2019 |
GN
| Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Expos |
| 12/02/2019 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 12/02/2019 |
GN
| Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt's Lymphoma/Leukemia to Massachusetts General Hospital in Boston |
|